[^18F] FLuorthanatrace PET/CT for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new imaging method for detecting cancer cells in individuals with ovarian, fallopian tube, or primary peritoneal cancer. The key component is a special imaging agent called fluorine F 18 fluorthanatrace, which is injected to help the PET/CT scanner produce clearer images of tumors. The goal is to determine if this method identifies more tumor cells than current techniques. Suitable candidates have a known or suspected solid tumor and at least one tumor visible on standard imaging scans. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative imaging method.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What prior data suggests that fluorine F 18 fluorthanatrace is safe for imaging in patients with solid tumors?
Research has shown that Fluorine F 18 Fluorthanatrace, a special imaging substance, has been tested in ovarian and breast cancer studies. These studies suggest it can target specific proteins in cancer cells, enhancing imaging results.
This trial phase primarily checks if patients can manage the side effects. As a Phase 1 trial, it assesses safety and side effects in a small group, so detailed safety information may still be limited. However, the goal is to ensure any side effects remain manageable. For participants, the main focus is on confirming the treatment's safety before advancing to further stages.12345Why are researchers excited about this trial?
Researchers are excited about using Fluorine F 18 Fluorthanatrace in ovarian cancer imaging because it offers a unique way to visualize the disease. Unlike standard imaging methods like FDG PET/CT that highlight glucose metabolism, Fluorine F 18 Fluorthanatrace targets a specific protein involved in DNA repair, which is often elevated in cancer cells. This could provide more precise information about tumor biology, potentially leading to better-targeted treatments. Additionally, the distinct mechanism of action may help detect cancer earlier and monitor treatment response more effectively.
What evidence suggests that this imaging technique is effective for detecting ovarian cancer?
Research has shown that Fluorine F 18 fluorthanatrace, a type of radioactive tracer, could be useful in detecting ovarian cancer. This tracer targets a specific enzyme called PARP-1, often found in cancer cells. Studies have found that the tracer's presence links to PARP-1 in ovarian tumors, suggesting it might help doctors identify cancer cells more accurately. In this trial, participants will receive Fluorine F 18 fluorthanatrace and undergo [18F]FTT PET/CT imaging. Early results from trials in both ovarian and breast cancer suggest it could be effective for imaging.12678
Who Is on the Research Team?
Lilie L. Lin
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for patients with solid tumors, such as ovarian, fallopian tube, or primary peritoneal cancer. Participants must have at least one tumor lesion of 1.0 cm visible on standard imaging. Pregnant or breastfeeding women and those unable to tolerate imaging procedures are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive FDG IV and undergo FDG PET/CT scan, followed by fluorine F 18 fluorthanatrace IV and [18F]FTT PET/CT
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- Fluorine F 18 Fluorthanatrace
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator